T

he US Army is proceeding with plans to grant Sanofi Pasteur an exclusive license to develop a vaccine for the Zika virus, despite concerns among some lawmakers and advocacy groups that the product may be priced too high for many Americans, even though it was developed with taxpayer funds.

In explaining its decision, an Army official wrote in a recent letter to one of the advocacy groups that the Army “lacks the means, expertise, and authority to define, implement, and enforce ‘affordable prices’ or to set price controls for a potential vaccine that will require great investment and face high risk of failure.” Citing confidentiality, the official declined to reveal specifics of the deal.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy